Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Accumulated Expenses: 2013-2025

Historic Accumulated Expenses for Amphastar Pharmaceuticals (AMPH) over the last 12 years, with Sep 2025 value amounting to $150.3 million.

  • Amphastar Pharmaceuticals' Accumulated Expenses rose 26.12% to $150.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $150.3 million, marking a year-over-year increase of 26.12%. This contributed to the annual value of $126.5 million for FY2024, which is 86.29% up from last year.
  • Amphastar Pharmaceuticals' Accumulated Expenses amounted to $150.3 million in Q3 2025, which was up 20.56% from $124.7 million recorded in Q2 2025.
  • In the past 5 years, Amphastar Pharmaceuticals' Accumulated Expenses ranged from a high of $198.7 million in Q2 2023 and a low of $63.7 million during Q4 2022.
  • In the last 3 years, Amphastar Pharmaceuticals' Accumulated Expenses had a median value of $123.1 million in 2025 and averaged $122.5 million.
  • Per our database at Business Quant, Amphastar Pharmaceuticals' Accumulated Expenses soared by 198.38% in 2023 and then slumped by 49.96% in 2024.
  • Quarterly analysis of 5 years shows Amphastar Pharmaceuticals' Accumulated Expenses stood at $67.3 million in 2021, then decreased by 5.33% to $63.7 million in 2022, then rose by 6.57% to $67.9 million in 2023, then skyrocketed by 86.29% to $126.5 million in 2024, then increased by 26.12% to $150.3 million in 2025.
  • Its last three reported values are $150.3 million in Q3 2025, $124.7 million for Q2 2025, and $123.1 million during Q1 2025.